Navigation Links
Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
Date:10/1/2008

Intermezzo(R) (zolpidem tartrate sublingual lozenge) developed to be the

first sleep aid specifically for use in the middle of the night when

patients awaken and have difficulty returning to sleep

PT. RICHMOND, Calif., Oct. 1 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate, Intermezzo(R) (zolpidem tartrate sublingual lozenge). Intermezzo(R) is a low dose, buffered, sublingual formulation of zolpidem intended to be the first prescription sleep aid to be indicated for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.

The Intermezzo(R) NDA submission follows the successful completion of two Phase 3 clinical trials. The first Intermezzo(R) Phase 3 trial was a double-blind, placebo-controlled crossover sleep laboratory study of 82 patients, which Transcept believes to be among the largest reported sleep laboratory studies of its type. This objective study demonstrated that the Intermezzo(R) 1.75 mg and 3.5 mg doses, when used at the time of a middle of the night awakening, significantly shortened the time for patients to return to sleep as compared to placebo, and there was no evidence of next day residual sedative effects with either dose. Transcept believes that these are the lowest zolpidem doses that have been reported to be statistically superior to placebo in producing sleep. When patients used the 3.5 mg dose, the study also indicated statistically significant improvements in total sleep time, sleep efficiency, subjective number of post-dose awakenings, sleep quality, level of refreshed sleep, and next day ability to function.

The second Phase 3 clinical trial was a double-blind, placebo-controlled outpatient study in which 294 patients used either In
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
2. Critical Pharmaceuticals Enter Sustained Release hGH Arena
3. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
4. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
5. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
6. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
7. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
9. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
10. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
11. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s ... dental, animal health and medical practitioners, announced today that the ... , September 4, 2014 – Baird 2014 Healthcare Conference ... ET , September 8, 2014 – Morgan ... , NY at 1:25 p.m. ET Henry Schein,s ...
(Date:8/21/2014)... PARK, N.J. , Aug. 21, 2014 /PRNewswire/ ... pharmacy group purchasing organization (GPO), is pleased to ... to collaborate on a host of innovative specialty ... help Aurora deliver enhanced therapy management services to ... Management (OTM) system. Aurora will use ...
(Date:8/21/2014)... WOONSOCKET, R.I. , Aug. 21, 2014 CVS ... early tender results, applicable Reference Yields and consideration payable in ... Offers") commenced on August 7, 2014 for (1) any and ... and All Notes") and (2) up to a maximum amount ... due 2041 and 5.750% Senior Notes due 2017 (collectively, the ...
Breaking Medicine Technology:Henry Schein To Present At Two Investor Conferences In September 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6
... Ill., Nov. 8, 2010 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... 8, 2010 Reportlinker.com announces that a ... its catalogue: The Future ... leading companies, and opportunities for target expansion ... G-Protein-coupled receptors (GPCRs) constitute the largest ...
Cached Medicine Technology:Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 2Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 3Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 4Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 5Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 6Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 7Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 8The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 2The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 3The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 4The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 5
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... American Corporate Health, was recently recognized as ... professionals in the field of workers’ compensation. ... Workers’ Compensation and Occupational Medicine Conference was ... attorneys, physicians, nurses, case managers, disability specialists, ...
(Date:8/21/2014)... As part of a continuing mission to ... joined with the Alliance for Safe Online Pharmacies (ASOP) ... sale of medicines. , “Helping to ensure the quality, ... a core mission for USP and an important tool ... T. Piervincenzi, chief executive officer of USP. “The illegal ...
(Date:8/21/2014)... 21, 2014 According to a new ... Optics Market-Global Industry Analysis, Size, Share, Growth, Trends and ... market was valued at USD 863.1 million in 2013 ... 7.6% from 2013 to 2019, to reach an estimated ... medical fiber optics market is witnessing significant growth due ...
(Date:8/21/2014)... According to a new market report ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... valued at USD 236.1 million in 2011 and is ... in 2018 at a CAGR of 6.3% from 2012 ... Report: http://www.transparencymarketresearch.com/fundus-cameras.html . , Fundus cameras market growth ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The worlds ... offer customers an exciting chance to grab free products. ... all-natural deodorant from Tom's of Maine with all qualifying ... deodorant and our environmentally friendly yoga apparel is simply ... The joint promotion between the two brands is intended ...
Breaking Medicine News(10 mins):Health News:Dr. Vasili Gatsinaris Named One of the Top 50 Most Influential in Workers’ Compensation 2Health News:USP Joins Efforts to Halt Illegal Online Drug Sales 2Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 2Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 3Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 4Health News:Fundus Cameras Market: Product Type- Mydriatic, Non-Mydriatic, Hybrid and ROP Cameras; End Users- Hospitals, Ophthalmology Clinics and Ophthalmic & Optometrist Offices 2Health News:Tom's of Maine Partner up with BaliniSports Yoga Apparel 2
... and Company) (NYSE: BDX ), a global medical ... Bear Stearns 20th Annual,Healthcare Conference on Monday, September 10, ... of BD,s presentation can be accessed from the BD,corporate ... for replay,through Monday, September 17, 2007. BD, a ...
... Pa., Aug. 30 As part of his work,to ... health,insurance, Governor Edward G. Rendell today said 35,000 uninsured,individuals ... Insurance,Program will be given the opportunity to receive health ... insurance brings a sense of security and peace of ...
... pathway in the most common and aggressive type of ... to fuel tumor growth and help cancers evade drug ... In a series of laboratory and animal experiments, Johns ... with an experimental compound called cyclopamine to explore the ...
... reduce or prevent allergic reactions, group suggests , THURSDAY, ... people with seasonal allergies may suffer oral allergy syndrome ... pollen proteins from weeds, grass and trees and similar ... symptoms of OAS -- also known as pollen-food syndrome ...
... The sort of swelling that occurs when a joint ... the healing process, but when it comes to the knee, ... findings in experiments with pigs may lead to treatments for ... Medical Center orthopedic researchers. There are drugs that can block ...
... with the respiratory condition , , WEDNESDAY, Aug. 29 (HealthDay ... guidelines Wednesday that seek to make breathing easier and ... the lung disease. , "Asthma control is achievable for ... the National Heart, Lung, and Blood Institute, said during ...
Cached Medicine News:Health News:Governor Rendell Offers adultBasic Coverage to 35,000 Uninsured Pennsylvanians 2Health News:Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells 2Health News:Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells 3Health News:Pollen, Fruits, Veggies Help Trigger Oral Allergy Syndrome 2Health News:New insights into common knee injuries 2Health News:New Asthma Guidelines Stress Disease Control 2Health News:New Asthma Guidelines Stress Disease Control 3
For the quantitative determination of Glycohemoglobin in blood....
For the quantitative determination of Glycohemoglobin (HbA1) in blood by,cation exchange resin. The test is to be used to monitor long-term glucose,control in diabetes mellitus....
... storage protein for iron. The ferritin molecule ... of heavy and light subunits, which surrounds ... phosphate [1]. Ferritin is synthesized in the ... with major concentrations found in the liver, ...
Rapid turn-around time, results in less than 4 hours...
Medicine Products: